The Food and Drug Administration uses Abbyy's artificial intelligence-based information technology platform to simplify the process of analyzing data from pre-marketing clinical trial safety reports on experimental drugs, GCN reported Wednesday.
Milpitas, California-based Abbyy and the FDA trained the company-built Digital Intelligence platform to extract and transform content in each report containing as many as 100 pages into structured data prior to the review process.
“We found that we can just drop 100,000 files in, have them process over the course of a week and almost all of them were recognized,“ Justin Scott, senior business informatics officer at the FDA, told the publication.
Scott added the platform had an accuracy rate of 99.3 percent in the early adoption phase, according to the report.
The FDA expects the technology to help the agency save 7,500 hours annually throughout its review process.